CompareMarketResearchRequest a sample
Home / Healthcare / MRI-based Quantitative Biomarkers

Healthcare · Market report

MRI-based Quantitative Biomarkers Market Size, Share and Forecast 2026-2036

The global MRI-based quantitative biomarkers market is worth USD 348 mn in 2026 and is forecast to reach USD 1.4 bn by 2036, growing at a 15.0% CAGR. United States is the largest country market and Brain and neuro is the largest by organ segment.

USD 348 mnMarket size 2026
USD 1.4 bnForecast 2036
15.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global MRI-based quantitative biomarkers market is worth USD 348 mn in 2026 and is forecast to reach USD 1.4 bn by 2036, growing at a 15.0% CAGR. United States is the largest country market and Brain and neuro is the largest by organ segment.

ScopeSoftware and reading services that extract numeric measures from MRI scans, such as liver fat and fibrosis, brain volume, cardiac and prostate metrics, sold to hospitals, trial sponsors and imaging centres.
IndustryHealthcare
Value 2025USD 300 mn
Value 2026USD 348 mn
Value 2036USD 1.4 bn
CAGR 2026-203615.0%
Volume 20261.39 million scans
Volume 20365.63 million scans
Average price 2026USD 250 per scan
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

MRI-based Quantitative Biomarkers market size and forecast, 2026-2036

Exhibit 1The global MRI-based quantitative biomarkers market is forecast to grow from USD 348 mn in 2026 to USD 1.4 bn by 2036, more than triplingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 15.0%
MRI-based Quantitative Biomarkers market value, 2025 to 2036Market value by year. 2025: USD 300 mn; 2026: USD 348 mn; 2027: USD 400 mn; 2028: USD 460 mn; 2029: USD 529 mn; 2030: USD 609 mn; 2031: USD 700 mn; 2032: USD 805 mn; 2033: USD 926 mn; 2034: USD 1.1 bn; 2035: USD 1.2 bn; 2036: USD 1.4 bn. Compound annual growth rate 2026 to 2036: 15.0%.2025348 mn2026700 mn20311.4 bn203615.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 348 mn
2027USD 400 mn
2028USD 460 mn
2029USD 529 mn
2030USD 609 mn
2031USD 700 mn
2032USD 805 mn
2033USD 926 mn
2034USD 1.1 bn
2035USD 1.2 bn
2036USD 1.4 bn

MRI-based Quantitative Biomarkers market segmentation

By organ

Exhibit 2Brain and neuro is the largest segment by organ, with 34.0% of 2026 revenueEstimated share of 2026 global revenue, by organ
MRI-based Quantitative Biomarkers market share by organ, 2026Share of 2026 revenue by organ. Brain and neuro: 34.0%; Liver: 26.0%; Prostate and oncology: 16.0%; Cardiac: 14.0%; Musculoskeletal and other: 10.0%.Brain and neuro34.0%Liver26.0%Prostate and oncology16.0%Cardiac14.0%Musculoskeletal and other10.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Brain and neuro34.0%35.9%USD 118 mn15.6%
Liver26.0%25.2%USD 90 mn14.6%
Cardiac14.0%12.4%USD 49 mn13.6%
Prostate and oncology16.0%18.4%USD 56 mn16.6%
Musculoskeletal and other10.0%8.1%USD 35 mn12.6%

By customer

Exhibit 3Hospitals and imaging centres adds the most revenue by customer, growing from USD 181 mn in 2026 to USD 770 mn by 2036Estimated revenue in USD by customer, 2026 and 2036 forecast
MRI-based Quantitative Biomarkers market by customer, 2026 and 2036Revenue by customer in 2026 and 2036. Hospitals and imaging centres: USD 181 mn in 2026, USD 770 mn in 2036, change +325%; Pharma and clinical trials: USD 139 mn in 2026, USD 543 mn in 2036, change +290%; Research institutes: USD 28 mn in 2026, USD 95 mn in 2036, change +242%.20262036 forecastChangeHospitals and imaging centres+325%181 mn770 mnPharma and clinical trials+290%139 mn543 mnResearch institutes+242%28 mn95 mn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Hospitals and imaging centres52.0%54.7%USD 181 mn15.6%
Pharma and clinical trials40.0%38.6%USD 139 mn14.6%
Research institutes8.0%6.8%USD 28 mn13.1%

By biomarker type

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Volumetric and structural30.0%27.0%USD 104 mn13.8%
Perfusion and diffusion24.0%25.0%USD 84 mn15.5%
Functional and connectivity18.0%22.0%USD 63 mn17.3%
Tissue composition (fat, iron, fibrosis)28.0%26.0%USD 97 mn14.2%

By software model

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Cloud-based analysis34.0%42.0%USD 118 mn17.5%
On-premise software46.0%38.0%USD 160 mn12.8%
Scanner-embedded modules20.0%20.0%USD 70 mn15.0%

By field strength

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Standard field systems48.0%40.0%USD 167 mn12.9%
High field systems42.0%45.0%USD 146 mn15.8%
Ultra-high field systems10.0%15.0%USD 35 mn19.8%

Top 25 countries for MRI-based quantitative biomarkers by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 90.5% of 2026 revenue and the 25 countries below together hold 97.1%.

Exhibit 4United States is the largest country market at USD 160 mn in 2026, and the three largest countries hold 62.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
MRI-based Quantitative Biomarkers market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 160 mn, 46.0%; Germany: USD 28 mn, 8.0%; United Kingdom: USD 28 mn, 8.0%; China: USD 24 mn, 7.0%; Japan: USD 21 mn, 6.0%; France: USD 14 mn, 4.0%; Netherlands: USD 10 mn, 3.0%; Canada: USD 10 mn, 3.0%; South Korea: USD 10 mn, 3.0%; Italy: USD 8.7 mn, 2.5%.United States160 mn 46.0%Germany28 mn 8.0%United Kingdom28 mn 8.0%China24 mn 7.0%Japan21 mn 6.0%France14 mn 4.0%Netherlands10 mn 3.0%Canada10 mn 3.0%South Korea10 mn 3.0%Italy8.7 mn 2.5%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 160 mn46.0%USD 612 mn14.4%
2GermanyUSD 28 mn8.0%USD 111 mn14.9%
3United KingdomUSD 28 mn8.0%USD 111 mn14.9%
4ChinaUSD 24 mn7.0%USD 137 mn18.8%
5JapanUSD 21 mn6.0%USD 76 mn13.8%
6FranceUSD 14 mn4.0%USD 55 mn14.7%
7NetherlandsUSD 10 mn3.0%USD 42 mn15.0%
8CanadaUSD 10 mn3.0%USD 42 mn15.0%
9South KoreaUSD 10 mn3.0%USD 54 mn17.8%
10ItalyUSD 8.7 mn2.5%USD 35 mn15.0%
11SpainUSD 4.6 mn1.3%USD 18 mn14.8%
12AustraliaUSD 4.0 mn1.1%USD 16 mn14.8%
13SwitzerlandUSD 3.1 mn0.9%USD 12 mn14.7%
14SwedenUSD 2.4 mn0.7%USD 9.4 mn14.8%
15DenmarkUSD 1.9 mn0.6%USD 7.6 mn14.8%
16BelgiumUSD 1.5 mn0.4%USD 6.0 mn14.7%
17IsraelUSD 1.3 mn0.4%USD 5.2 mn14.7%
18SingaporeUSD 1.0 mn0.3%USD 4.1 mn15.0%
19TaiwanUSD 0.77 mn0.2%USD 4.1 mn18.2%
20AustriaUSD 0.66 mn0.2%USD 2.7 mn15.0%
21BrazilUSD 0.56 mn0.2%USD 2.2 mn15.0%
22IndiaUSD 0.45 mn0.1%USD 1.8 mn15.0%
23PolandUSD 0.31 mn0.09%USD 1.3 mn15.0%
24Saudi ArabiaUSD 0.28 mn0.08%USD 1.4 mn17.6%
25NorwayUSD 0.21 mn0.06%USD 0.84 mn15.0%
Rest of worldUSD 9.9 mn2.9%USD 39 mn14.6%
Exhibit 5United States and China account for 53% of the USD 1.1 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
MRI-based Quantitative Biomarkers market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 348 mn. United States: +USD 452 mn; China: +USD 112 mn; Germany: +USD 83 mn; United Kingdom: +USD 83 mn; Japan: +USD 55 mn; 20 other countries: +USD 244 mn; Rest of world: +USD 29 mn. Market value 2036: USD 1.4 bn.Market value 2026348 mnUnited States+452 mnChina+112 mnGermany+83 mnUnited Kingdom+83 mnJapan+55 mn20 other countries+244 mnRest of world+29 mnMarket value 20361.4 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • Siemens Healthineers
  • GE HealthCare
  • Philips

Group 2: Regional and specialist players

  • Perspectum
  • Cortechs.ai
  • icometrix
  • Qmenta
  • Resonance Health
  • Circle Cardiovascular Imaging
  • Medis Medical Imaging
  • Combinostics
  • Quibim
  • Neurophet

Group 3: Emerging and niche players

  • Subtle Medical
  • Median Technologies
  • Pixyl
  • Bioxydyn
  • Intrasense
  • Qynapse

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the MRI-based quantitative biomarkers market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 15.0% is calculated from the resulting values.

The market is divided by organ, by customer, by biomarker type, by software model, by field strength. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the MRI-based quantitative biomarkers market?

The global MRI-based quantitative biomarkers market is estimated at USD 300 mn in 2025 and USD 348 mn in 2026.

How fast will the MRI-based quantitative biomarkers market grow?

It is forecast to reach USD 1.4 bn by 2036, a compound annual growth rate of 15.0% from 2026, an increase of USD 1.1 bn.

Which country is the largest market for MRI-based quantitative biomarkers?

United States is the largest market by revenue at USD 160 mn in 2026, 46.0% of the global total. The three largest countries together hold 62.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 18.8% a year from 2026 to 2036.

Which MRI-based quantitative biomarkers segment is largest?

In the by organ split, Brain and neuro is the largest segment with 34.0% of 2026 revenue.

Who are the leading MRI-based quantitative biomarkers companies?

Global leaders include Siemens Healthineers, GE HealthCare, Philips.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Lyophilization Equipment Mail Order Pharmacy →

All Healthcare markets →

Request a sample